Evidence map›Paper›PMID 32916598›Full record

ArticleMolecular therapy. Nucleic acids2020

ZEB1-Mediated Transcriptional Upregulation of circWWC3 Promotes Breast Cancer Progression through Activating Ras Signaling Pathway.

Lingjiao Meng, Sihua Liu, Fei Liu, Meijie Sang, Yingchao Ju, Xiaojie Fan, Lina Gu, Ziyi Li, Cuizhi Geng, Meixiang Sang

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Lingjiao MengResearch Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China.
Sihua LiuResearch Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China.
Fei LiuResearch Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China.
Meijie SangResearch Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China; Department of Surgical Nursing, Hebei University of Chinese Medicine, Xingyuan Road, Shijiazhuang, Hebei 050200, P.R. China.
Yingchao JuAnimal Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China.
Xiaojie FanResearch Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China; Pathology Department, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China.
Lina GuResearch Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China; Key Laboratory for Tumor Diagnosis, Prevention and Therapy in Hebei Province, Shijiazhuang, Hebei 050017, P.R. China.
Ziyi LiResearch Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China.
Cuizhi GengBreast Diagnostic and Therapeutic Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China. Electronic address: cuizhigeng@hotmail.com.
Meixiang SangResearch Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China; Key Laboratory for Tumor Diagnosis, Prevention and Therapy in Hebei Province, Shijiazhuang, Hebei 050017, P.R. China. Electronic address: mxsang@hotmail.com.
Hebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zinc finger E-box binding homeobox 1 (ZEB1) has been widely recognized as an important driver of tumor growth and metastasis. However, nothing is known about ZEB1-regulated circular (circ)RNAs in cancer. In the current study, we evaluated the function of a novel ZEB1-regulated circRNA derived from the WWC3 gene locus, circWWC3 in breast cancer progression. We found that ZEB1 upregulated circWWC3 expression but not the linear WWC3 mRNA expression. circWWC3 is highly expressed in breast cancer tissues and is associated with the poor prognosis of breast cancer patients. Silencing of circWWC3 significantly suppresses the proliferation, migration, and invasion of breast cancer cells. Mechanically, circWWC3 upregulates multiple oncogenes' expression of the Ras signaling pathway through acting as the sponge of microRNA (miR)-26b-3p and miR-660-3p. Moreover, short hairpin (sh)RNA-mediated knockdown of circWWC3 partially antagonized ZEB1-mediated breast cancer growth and metastasis in vivo. Our findings reveal that ZEB1-mediated upregulation of circWWC3 promotes breast cancer progression through activating Ras signaling pathway, which provides a potential therapeutic target and prognostic biomarker for breast cancer.

Indexed as

breast cancercircular RNAcircWWC3miR-26b-3pmiR-660-3pRas signaling pathwayZEB1

Identifiers

PMID32916598
PMCPMC7490471
OpenAlexW3079143505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.